Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy

Mostrar otras versiones (1)

To determine whether molecular parameters could be partly responsible for resistance or sensitivity to oxaliplatin (OX)-based chemotherapy used as first-line treatment in advanced colorectal cancer (CRC). We studied the usefulness of the excision repair cross-complementing 1 (ERCC1), xeroderma pigme...

Descripción completa

Detalles Bibliográficos
Autores principales: Paré, L, Marcuello, E, Altés, A, Río, E del, Sedano, L, Salazar, J, Cortés, A, Barnadas, A, Baiget, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567080/
https://www.ncbi.nlm.nih.gov/pubmed/18797464
http://dx.doi.org/10.1038/sj.bjc.6604671

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567080/
https://www.ncbi.nlm.nih.gov/pubmed/18797464
http://dx.doi.org/10.1038/sj.bjc.6604671

Ejemplares similares